Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole in Mild Autonomous Cortisol Secretion
NCT07649317Phase 1Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketoconazole in Autonomous Cortisol Secretion (ACS) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Difference in serum cortisol between MACS and HV at 0200 hours. Started Jul 2026; status: recruiting.
02
Drugs
ketoconazole
03
Conditions
Autonomous Cortisol Secretion (ACS)
Beyond the preview
Go deeper on NCT07649317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649317.